Nov 05, 2019 10:02 JST

Source: Eisai

Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma

TOKYO, Nov 05, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.

Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme, Inc. Under the terms of the March 2015 amended and restated agreement with Epizyme, Eisai is responsible for development and commercialization of tazemetostat within Japan, as well as paying to Epizyme royalties on net sales of tazemetostat in Japan. Epizyme is responsible for development and commercialization outside of Japan, and paying to Eisai certain development and regulatory milestones, as well as royalties on net sales of tazemetostat in all regions outside of Japan.

In this agreement with Royalty Pharma, Eisai transfers to Royalty Pharma its rights to receive royalties from Epizyme on sales outside of Japan. Eisai will receive an upfront payment of 110 million U.S. dollars for the transfer and obtain the right to receive up to an additional 220 million U.S. dollars upon marketing approvals for tazemetostat in the United States for certain indications.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. By the effective use of management resources including the funds obtained through this agreement, Eisai will accelerate to discover the new medicines based on the cutting- edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About Tazemetostat (Generic Name, Development Code: E7438, Epizyme's Development Code: EPZ-6438)

Created through Epizyme's proprietary product platform, tazemetostat is a first-in-class small-molecule inhibitor of the epigenetic enzyme EZH2. EZH2 is one of the proteins that make up the histone methyltransferases (HMTs) that alter gene expression. It is believed that EZH2 regulates cell proliferation, and may have an important role in carcinogenesis. In Japan, Eisai is currently conducting Phase II clinical studies for B-cell non-Hodgkin's lymphoma.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the industry leader in acquiring pharmaceutical royalties, with over $16 billion in royalty assets. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors). The company's portfolio includes royalty interests in over 50 approved products including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's cystic fibrosis franchise. Royalty Pharma is also a leading investor in pre-approval royalties, having since 2011 invested over $4 billion in royalties on pre-approval products and committed over $900 million to direct R&D funding in exchange for royalties. More information on Royalty Pharma is available at www.royaltypharma.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
June 02 2025 16:46 JST
 
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28 2025 16:45 JST
 
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 21 2025 14:00 JST
 
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
May 16 2025 16:21 JST
 
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
April 30 2025 13:17 JST
 
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
April 18 2025 15:52 JST
 
Eisai to Divest Rights for Pariet in China to Peak Pharma
April 01 2025 12:15 JST
 
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
March 25 2025 16:28 JST
 
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
March 25 2025 11:21 JST
 
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
March 10 2025 19:24 JST
 
More Press release >>

Latest Press Release


More Latest Release >>